Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has granted nearly 2.14 million stock options under its Stock Option Plan, including 1.86 million to directors and officers.
Priced at $0.30 per share, the options vest 25% every six months and expire in five years.
CEO David Regan said the options align with shareholder interests and compensate directors, who receive no cash. He added that the company is progressing toward a first-in-human trial of its THT cancer treatment, with initial results expected this summer.